Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.37 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612485 | 0.84 | EDNRA (0.66) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL28171584 | 0.82 | EDNRA (0.47) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL29104635 | 0.80 | KDM4E (0.39) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL27294093 | 0.79 | NPC1 (0.54) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL3608518 | 0.77 | RAB9A (0.76) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL353910 | 0.76 | KCNH2 (0.58) | NPC1RAB9AKDM4EHSD17B10MEN1 | |
| SCHEMBL5970712 | 0.75 | EDNRA (0.41) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL3244639 | 0.75 | POLB (0.50) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL27593861 | 0.75 | EDNRA (0.63) | EDNRANPC1RAB9AMAPTKDM4E | |
| SCHEMBL5506599 | 0.73 | NPC1 (0.62) | NPC1RAB9AMAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285518-A | Quinazoline derivative containing benzofuran structure and application thereof | 华侨大学 | 2023-12-26 | — | — | CN | claimed |
| CN-111018846-B | Crystalline forms of a compound | 和记黄埔医药（上海）有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-111018846-A | Crystal forms of compounds | 和记黄埔医药（上海）有限公司 | 2020-04-17 | — | — | CN | claimed |
| EP-3191475-A1 | CRYSTALLINE FORMS OF 6- ( (6, 7-DIMETHOXYQUINAZOLIN-4-YL) OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | Hutchison Medipharma Limited (CN) | 2017-07-19 | — | — | EP | claimed |
| WO-2016037550-A1 | CRYSTALLINE FORMS OF 6- ( (6, 7-DIMETHOXYQUINAZOLIN-4-YL) OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-17 | — | — | WO | claimed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | claimed |
| JP-2007516273-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | claimed |
| CN-117285518-A | Quinazoline derivative containing benzofuran structure and application thereof | 华侨大学 | 2023-12-26 | — | — | CN | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-111018846-B | Crystalline forms of a compound | 和记黄埔医药（上海）有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11603531-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2020098795-A1 | Pharmaceutical preparation of fruquintinib and use thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-05-22 | — | — | WO | disclosed |
| CN-111018846-A | Crystal forms of compounds | 和记黄埔医药（上海）有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3191475-A1 | CRYSTALLINE FORMS OF 6- ( (6, 7-DIMETHOXYQUINAZOLIN-4-YL) OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | Hutchison Medipharma Limited (CN) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016037550-A1 | CRYSTALLINE FORMS OF 6- ( (6, 7-DIMETHOXYQUINAZOLIN-4-YL) OXY) -N,2-DIMETHYLBENZOFURAN-3-CARBOXAMIDE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-17 | — | — | WO | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603531-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | EDNRA 2021/4885NPC1 2258/4885RAB9A 3071/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | EDNRA 2021/4885NPC1 2258/4885RAB9A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.